TLDR
- ImmunityBio reports scalable NK cell manufacturing across 64 subjects.
- Early trials show safe M-CENK cell therapy combined with ANKTIVA.
- The NK cell platform demonstrates strong cytotoxic activity in tumors.
- Phase I data supports expansion of ImmunityBio’s cell therapy program.
- Preclinical data shows tumor reduction with the M-CENK and ANKTIVA combo.
ImmunityBio stock trades near $8.25 as the company reported progress in its NK cell immunotherapy platform. The biotech firm completed manufacturing engineering programs that validated scalable production of M-CENK cells. The update also included early clinical safety results from a Phase I cancer trial.
ImmunityBio, Inc., IBRX
The company completed two manufacturing programs known as NK2022 and NK2023. These studies established a reproducible pathway from leukapheresis collection to therapeutic cell manufacturing. As a result, the platform demonstrated consistent NK cell production across different donor populations.
The combined studies enrolled 74 individuals, including healthy volunteers and cancer patients. The programs generated operational data needed for future clinical development. ImmunityBio strengthened the manufacturing foundation supporting its NK cell therapy pipeline.
Manufacturing Programs Confirm Scalable NK Cell Production
The NK2022 and NK2023 studies evaluated the safety of large-volume leukapheresis procedures. These programs also tested the reliability of NK cell enrichment and cytokine-driven programming. Researchers conducted the work across both healthy volunteers and cancer patients.
A total of 64 participants completed the leukapheresis collection process successfully. The procedures produced no serious adverse events linked to cell collection. Scientists then stored the collected cells for manufacturing development and validation activities.
Ten cancer patients later received NK cells processed through ImmunityBio’s enrichment system. Doctors administered 23 therapeutic doses during treatment cycles. The treatments demonstrated repeat dosing capability and successful cryo-banking of NK cell products.
Post-collection immune testing confirmed preserved NK cell activity in donors and patients. Importantly, NK cells derived from cancer patients showed strong tumor-killing ability. The cells matched the cytotoxic activity observed in NK cells from healthy donors.
Laboratory analysis tested NK cells against several tumor types. These included breast, ovarian, glioblastoma, lymphoma, and other cancer models. The results demonstrated broad antitumor activity across multiple cancer histologies.
Phase I Trial Shows Safety of NK Cell Therapy Combination
Manufacturing results enabled the launch of a Phase I clinical trial called QUILT-3.076. The study evaluated autologous M-ceNK cells combined with ANKTIVA therapy. The trial focused on patients with relapsed or treatment-resistant solid tumors.
Researchers enrolled ten patients in the treatment group. Participants received weekly intravenous NK cell infusions with subcutaneous ANKTIVA administration every two weeks. Treatment doses ranged from 0.25 to 0.75 billion cells per infusion.
The trial included several cancer types, including breast, colon, pancreatic, renal, and osteosarcoma tumors. All treatments occurred in outpatient clinical settings. The protocol allowed patients to receive multiple NK cell infusions during therapy.
Clinical monitoring reported no grade four or grade five treatment-related adverse events. Investigators also recorded no cases of cytokine storms during the treatment period. These findings demonstrated early safety for the NK cell therapy combination.
The therapy design combines NK cell transfer with ANKTIVA immune stimulation. ANKTIVA activates interleukin-15 pathways that promote NK cell survival. The treatment may support longer persistence of therapeutic immune cells.
Preclinical Data Demonstrates Antitumor Potential
The platform emerged from research presented at the AACR IO 2026 meeting. Scientists from the National Cancer Institute reported early preclinical findings. The study evaluated M-ceNK activity in neuroendocrine tumor models.
Researchers tested the therapy in xenograft models of small cell lung cancer. The NK cell and ANKTIVA combination reduced tumor volume significantly in both models. Statistical analysis confirmed strong tumor suppression results.
Investigators also observed increased MHC class I expression in residual tumor cells. This change could increase sensitivity to other immunotherapy approaches. The therapy may work alongside immune checkpoint treatments.
Neuroendocrine tumors often lack MHC class I expression and resist T-cell-based therapies. This characteristic makes them vulnerable to NK cell-mediated destruction. Consequently, NK cell therapy may address an important unmet treatment need.
Laboratory studies also showed strong NK cell activation markers and cytokine production. The cells released interferon-gamma and granzyme B when exposed to tumor targets. These findings indicate a highly cytotoxic immune response.
ImmunityBio continues developing therapies that activate both innate and adaptive immune responses. The company’s Cancer BioShield platform focuses on restoring immune system activity against tumors. NK cell therapies and cytokine stimulators remain central components of this strategy.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
